The goal of the TBCRC is to conduct innovative, high impact, biologically-driven translational and clinical research. Our mission is to lessen the burden of breast cancer by using a multidisciplinary approach to discover novel mechanisms of breast cancer pathogenesis and test innovative, basic science-based therapeutic strategies.
The Translational Breast Cancer Research Consortium (TBCRC) is a collaborative group founded in 2005 to conduct innovative and high-impact clinical trials for breast cancer. The TBCRC is composed of eighteen clinical sites, five core subcommittees/ working groups (WGs) comprised of a Correlative Science WG and four other groups organized around various breast cancer phenotypes (including the Triple Negative WG, the HER2 Resistance WG, the Endocrine Resistance WG, and the Locoregional Disease WG), four interest groups (IGs) including the Radiation Therapy, Patient Reported Outcomes, Immuno-Oncology, and Social Media IGs, the Diversity Task Force, a patient advocate WG, a study coordinator WG, a contracts/ administrators WG, and a Central Office. Collectively, these groups work together to foster trial development in a collegial environment that enhances cross-institutional collaborations.
Business Manager
Program Manager
University of Washington School of Medicine/Fred Hutchinson Cancer Research Center
University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center
Johns Hopkins University
Johns Hopkins University
University of Pittsburgh
Johns Hopkins University
Johns Hopkins University
University of Alabama at Birmingham Comprehensive Cancer Center
Georgetown University
Memorial Sloan Kettering Cancer Center
Baylor College of Medicine
Dana-Farber/ Harvard Cancer Center
Dana-Farber/ Harvard Cancer Center
University of Washington School of Medicine/Fred Hutchinson Cancer Research Center
Baylor College of Medicine
University of North Carolina at Chapel Hill
Duke University Medical Cancer Center
University of North Carolina at Chapel Hill
MD Anderson Cancer Center
University of California San Francisco
University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center
MD Anderson Cancer Center
ASCO
Baylor College of Medicine
University of Chicago Medical Center
Dana-Farber/ Harvard Cancer Center
Dana-Farber/Harvard Cancer Center
University of Pittsburgh
University of California San Francisco
Vanderbilt University
